In the Spotlight

Kinase-Dead BRAF and Oncogenic RAS Drive Tumor Progression through CRAF

The RAS-ERK (extracellular signal-regulated protein kinase) MAPK (mitogen-activated protein kinase) signaling pathway regulates cell responses to environmental cues that include survival, proliferation, senescence, and differentiation. But, it also plays an important role ...Read More

Spectrum Pharmaceuticals Licenses Belinostat to TopoTarget

Spectrum Pharmaceuticals has entered into a co-development and commercialization ... 

Abbott and Pierre Fabre to Develop and Commercialize Pre-Clinical mAb

Abbott has signed an exclusive worldwide licensing agreement with Pierre Fabre SA ...

Tenx Biopharma Licenses Zanolimumab from Genmab

TTenX Biopharma has signed a licensing agreement to acquire exclusive worldwide rights...

BioMarin to Acquire LEAD Therapeutics

BioMarin Pharmaceutical has entered into a stock purchase agreement to acquire LEAD ...

3SBio and Ascentage Pharma to Develop and Commercialize Cancer Therapeutics

3SBio and Ascentage Pharma Group Corporation announced the formation of a strategic alliance ...

Read More

Phosphorylation by Cdk2 is Required for Myc to Repress Ras-induced Senescence

It has been known for over two decades that no more than two activated oncogenes...

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Kinase inhibitors have emerged as effective clinical therapies for cancers ...

Chemical Proteomics Native Target Profiling of INNO-406 in CML Cells

Expression of the oncogenic fusion protein BCR-ABL is the hallmark of chronic ...

Mutant p53 Drives Invasion by Promoting Integrin Recycling

p53 is a tumor suppressor protein whose function is frequently lost in cancers ...

Read More

Denosumab Superior to Zometa in Prostate Cancer Patients with Bone Metastases

Amgen announced that a pivotal, Phase III, head-to-head trial evaluating ...

Phase II Trial of Picoplatin in mCRC meets Primary Endpoint

Poniard Pharmaceuticals presented final data from a randomized, controlled ...

Phase III Trial of Sutent in Patients with Pancreatic NETs meets Primary Endpoint

Pfizer announced final results from a randomized Phase III trial of Sutent ...

Survival Benefits with KRX-0401 in mCRC Treatment

Keryx Biopharmaceuticals reported updated results from a Phase II trial ...

Read More

At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and bio tech companies. We currently work with leading pharmaceutical and biotech firms globally.

CLICK HERE to visit SMARTANALYST

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer

Mutations within the KRAS proto-oncogene have predictive value...

DNA Methylation Signatures Identify Biologically Distinct Subtypes in AML

It has been appreciated in recent years that there are chemical codes ...

AstraZeneca and Dako to Develop Companion Diagnostics for Cancer Treatments

AstraZeneca and Dako Denmark have entered into a collaboration ...

Read More

Herceptin Approved in EU for HER2-Positive Advanced Gastric Cancer

Roche announced that the European Commission has approved Herceptin ...

TYKERB Receives Accelerated Approval for 1st line Combination Treatment of HR+, HER2+/ErbB2+ Metastatic BC

GlaxoSmithKline announced that the FDA has granted accelerated approval ...

FDA Approves Rituxan plus Chemotherapy for CD20-positive CLL

Genentech and Biogen Idec announced that the FDA has approved Rituxan ...

Tasigna Receives FDA Priority Review for Newly Diagnosed Patients with Early-stage CLL

Novartis announced that Tasigna (nilotinib), a Bcr-Abl-tyrosine-kinase-inhibitor ...

Read More

The E-newsletter team: Dr. Anuradha Dhingra, Ms.Meenu Grover, Dr. Shirish Kumar, Ms. Sarika Manchanda, Dr. Vinamrata Bhatia. Copyright©2010 SMARTANALYST INDIA PVT LTD. All rights reserved CLICK HERE unsubscribe from the list